Narayana Hrudayalaya Q1 FY27 Results Analysis: PAT Jumps 58%, EBITDA Margin Compresses 511bps (NH)
Narayana Hrudayalaya Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 2,683.63 Cr (+78.05% YoY) and PAT growth of +5.72% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 31, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 2,683.63 Cr (+78.05% YoY) |
| PAT (Q1) | Rs. 207.27 Cr (+5.72% YoY) |
| EBITDA margin | 18.82% (-511 bps YoY) |
| EPS (Q1) | Rs. 10.20 (+5.70% YoY) |
| Market cap | Rs. 41,487.84 Cr |
| CMP | Rs. 2,029.20 |
Quarter Snapshot
Standalone India business delivered strong 16.3% revenue growth and 57.8% PAT growth with expanding margins, indicating healthy core operations. However, consolidated results are weighed down by UK acquisition margin dilution (EBITDA margin compressed 511bps YoY) and a widening insurance loss (Rs.62.5 Cr per quarter). The UK integration trajectory and insurance turnaround are critical for future performance.
Key Investment Insights
Key Positives
- Standalone revenue grew 16.3% YoY to Rs.1,097 Cr
- Standalone PAT grew 57.8% YoY to Rs.137.85 Cr
- Standalone EBITDA margin expanded 385 bps YoY to 24.57%
- Consolidated revenue grew 78% YoY to Rs.2,683.6 Cr, driven by full quarter of UK acquisition
- Debt/equity improved sequentially from 1.29x to 1.24x
- No exceptional items in Q1 FY27; auditor's report clean
- Medical supplies cost improved to 19.16% of revenue from 20.29% YoY
Risk Factors
- Consolidated EBITDA margin compressed 511 bps YoY and 197 bps QoQ to 18.82%
- PAT-to-owners grew only 5.35% despite 78% revenue growth
- Insurance segment loss widened to Rs.62.5 Cr from Rs.24 Cr YoY, annualising ~Rs.250 Cr drag
- Medical segment margin compressed sequentially to 14.73% from 16.66%
- Finance costs rose 92% YoY to Rs.86.8 Cr due to UK acquisition debt
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.